Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Gentisic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.59 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 6/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.59 |
| ▸ | CA12 | O43570 | 5/20 | 0.59 |
| ▸ | CA7 | P43166 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gentisic Acid SCHEMBL8084108 | 1.00 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL28741734 | 1.00 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL29395432 | 0.98 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL453133 | 0.98 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL1115092 | 0.93 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL7261031 | 0.93 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL8921890 | 0.93 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10984737 | 0.93 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL3981502 | 0.93 | CA12 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL1457617 | 0.93 | CA1 (0.61) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616738-B2 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | NOVO NORDISK A/S (DK) | 2026-05-05 | — | — | US | claimed |
| CN-122094704-A | Formulations for oral administration of active agents comprising a combination of acid-neutralizing polymer and non-polymeric material | — | 2026-05-26 | — | — | CN | disclosed |
| US-12616738-B2 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | NOVO NORDISK A/S (DK) | 2026-05-05 | — | — | US | disclosed |
| US-20260069727-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES | Clarity Pharmaceuticals Ltd (AU) | 2026-03-12 | — | — | US | disclosed |
| EP-4674479-A2 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Novo Nordisk A/S (DK) | 2026-01-07 | — | — | EP | disclosed |
| EP-2970875-B2 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| EP-4142695-B1 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND HISTIDINE | NOVO NORDISK AS (DK) | 2025-11-05 | — | — | EP | disclosed |
| EP-3790575-B1 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | NOVO NORDISK AS (DK) | 2025-07-30 | — | — | EP | disclosed |
| EP-4572807-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES | Clarity Pharmaceuticals Limited (AU) | 2025-06-25 | — | — | EP | disclosed |
| CN-115461044-B | Solid compositions comprising GLP-1 agonist and histidine | 诺和诺德股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20230087952-A1 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | NOVO NORDISK AS (DK) | 2023-03-23 | — | — | US | disclosed |
| EP-4142695-A1 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND HISTIDINE | NOVO NORDISK A/S (DK) | 2023-03-08 | — | — | EP | disclosed |
| US-20230000949-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | NOVO NORDISK AS (DK) | 2023-01-05 | — | — | US | disclosed |
| US-20220395559-A1 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, AN SGLT2 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | NOVO NORDISK AS (DK) | 2022-12-15 | — | — | US | disclosed |
| US-20220313600-A1 | FORMULATIONS OF PSMA IMAGING AGENTS | Clarity Pharmaceuticals Limited (AU) | 2022-10-06 | — | — | US | disclosed |
| EP-4054520-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Novo Nordisk A/S (DK) | 2022-09-14 | — | — | EP | disclosed |
| EP-4054536-A1 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, AN SGLT2 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Novo Nordisk A/S (DK) | 2022-09-14 | — | — | EP | disclosed |
| CN-114641276-A | Solid compositions comprising a GLP-1 agonist, an SGLT2 inhibitor, and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid | 诺和诺德股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114641275-A | Solid compositions comprising a PCSK9 inhibitor and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid | 诺和诺德股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-3976025-A1 | FORMULATIONS OF PSMA IMAGING AGENTS | Clarity Pharmaceuticals Limited (AU) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395559-A1 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, AN SGLT2 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | SLC5A2, SLC5A1, GLP1R | ALOX5 2107/4885PTGS2 757/4885CA1 1779/4885 |
| US-20230000949-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | PCSK9, EGFR, PCSK6 | ALOX5 3580/4885PTGS2 4224/4885CA1 3082/4885 |
| US-20230087952-A1 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | GLP1R, GIPR, IAPP | ALOX5 3536/4885PTGS2 2607/4885CA1 915/4885 |
| US-12616738-B2 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | SLC5A1, GLP1R, SLC5A2 | ALOX5 3897/4885PTGS2 724/4885CA1 1173/4885 |
| US-20260069727-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES | GALR1, HCAR1, CA12 | ALOX5 1315/4885PTGS2 1719/4885CA1 64/4885 |
| US-20220313600-A1 | FORMULATIONS OF PSMA IMAGING AGENTS | KLK3, FOLH1, PSMA1 | ALOX5 4490/4885PTGS2 4111/4885CA1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.